Contaminants in commercial preparations of melatonin

Mayo Clinic Proceedings

Volumn 72, Issue 11, 1997, Pages 1094-1095

  Williamson, Brian L ^a   Tomlinson, Andrew J ^a   Naylor, Stephen ^a   Gleich, Gerald J ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MELATONIN;

CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG CONTAMINATION; DRUG INDUSTRY; EOSINOPHILIA MYALGIA SYNDROME; HUMAN; LETTER;

DRUG CONTAMINATION; DRUG INDUSTRY; EOSINOPHILIA-MYALGIA SYNDROME; HUMANS; MELATONIN;

EID: 0031278737     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-6196(11)63555-6     Document Type: Letter

References (7)

1. Swygert LA, Macs EF, Sewell LE, Miller L, Falk H, Kilbourne EM, et al. Eosinophilia-myalgia syndrome: results of national surveillance. JAMA 1990;264:1698-1703
2. Hill RH Jr, Caudill SP, Philen RM, Bailey SL, Flanders WD, Driskell WJ, et al. Contaminants in L-tryptophan associated with eosinophilia myalgia syndrome. Arch Environ Contam Toxicol 1993 ; 25:134-142
3. Mayeno AN, Lin F, Foote CS, Loegering DA, Ames MM, Hedberg CW, et al. Characterization of peak E, a novel amino acid associated with eosinophilia-myalgia syndrome. Science 1990;250:1707-1708
4. Silver RM. Unraveling the eosinophilia-myalgia syndrome [editorial]. ArchDermatol 1991;127:1214-1216
5. Wurtman R. Presented at Annual Summer Toxicology Forum, Session 7: Free Amino Acids; 1990 Jul 19; Aspen (CO)
6. Lamberg L. Melatonin potentially useful but safety, efficacy remain uncertain. JAMA 1996;276:1011-1014
7. Kamb ML, Murphy JJ, Jones JL, Gaston JC, Nederlof K, Horney LF, et al. Eosinophilia-myalgia syndrome in L-tryptophan-exposed patients. JAMA 1992;267:77-82